The goal of this observational study is to learn about in describe treatment pattern and clinical outcomes in patients with HER2-overexpressed advanced solid tumors after progression of first-line standard therapy. The main questions it aims to answer are: * To evaluate the real-world safety and efficacy of Disitamab Vedotin in second-line and beyond treatment of advanced solid tumors with HER2 overexpression * To describe the treatment pattern and clinical outcomes of patients with advanced gastric cancer with HER2 overexpression in real world Settings after the failure of first-line standard therapy.
No linked publications found in PubMed
Inclusion Criteria: * Signing informed consent and agreeing to comply with study requirements; * Age ≥18 years old, gender unlimited; * ECOG physical status 0-2 points; * Patients with locally advanced or metastatic solid tumors confirmed histologically or cytologically;Cohort1-2 cohort: patients who had received at least previous first-line standard therapy (HER2 IHC3+ or IHC2+/FISH+ patients with first-line trastuzumab (or its biosimilar) combined with chemotherapy (fluorouracil and/or platinum-based chemotherapy);IHC2+/FISH- patients with first-line Immunotherapy combined with chemotherapy (fluorouracil and/or platinum-based chemotherapy) or chemotherapy alone);In Cohort3 cohort, patients received at least the standard first-line treatment clearly recommended by the guidelines. Patients with clear disease progression confirmed by the investigator or documented history. * HER2 overexpression was defined as 2+ or 3+ immunohistochemistry (both primary and metastatic tumor tissue were acceptable), and previous patient test results (confirmed by the investigator) or center test results were acceptable. * Have measurable or evaluable lesions according to RECIST1.1 criteria; * The investigator evaluated that the patients would benefit from the study treatment; * Good compliance, willing and able to follow the trial and follow-up procedures; * Have traceable patient medical records. Exclusion Criteria: * Known hypersensitivity or delayed allergic reactions to certain components of the study drug or similar drugs; * Participating in any interventional clinical trials; * The investigator assessed inappropriate inclusion.